Jacc-hf reports successful heart failure trial with daxor bva-100®

Researchers call for larger clinical trial citing outcomes from study oak ridge, tn, aug. 10, 2023 (globe newswire) -- daxor corporation (nasdaq: dxr), the global leader in blood volume measurement technology, today announces a research letter in the journal of the american college of cardiology – heart failure reporting on the successful results of a pilot 31 patient randomized control trial (rct) conducted by the duke clinical research institute utilizing daxor's bva-100 diagnostic to measure clinician assessment accuracy and the impact of optimizing decongestion therapy for heart failure patients with the diagnostic. the study results showed that all patients had marked volume derangements, but that in over 68% of the cases care teams did not correctly diagnose the volume state of the patient by clinical exam when compared to bva.
DXR Ratings Summary
DXR Quant Ranking